company background image
GLYC

GlycoMimetics NasdaqGM:GLYC Stock Report

Last Price

US$2.29

Market Cap

US$120.1m

7D

11.7%

1Y

49.7%

Updated

04 Dec, 2022

Data

Company Financials +
GLYC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

GLYC Stock Overview

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States.

GlycoMimetics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for GlycoMimetics
Historical stock prices
Current Share PriceUS$2.29
52 Week HighUS$2.43
52 Week LowUS$0.51
Beta1.86
1 Month Change230.83%
3 Month Change211.40%
1 Year Change49.67%
3 Year Change-61.77%
5 Year Change-84.70%
Change since IPO-74.58%

Recent News & Updates

Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely

Oct 06
Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely

GlycoMimetics has a new Chief Medical Officer

Sep 06

Recent updates

Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely

Oct 06
Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely

GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely

Jun 04
GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely

Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Nov 20
Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully

Aug 20
We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully

Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year

May 12
Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Mar 26
Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares

Feb 19
GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares

GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings

Jan 24
GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings

How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?

Dec 28
How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Dec 07
Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Shareholder Returns

GLYCUS BiotechsUS Market
7D11.7%4.2%1.5%
1Y49.7%-7.4%-14.9%

Return vs Industry: GLYC exceeded the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: GLYC exceeded the US Market which returned -14.9% over the past year.

Price Volatility

Is GLYC's price volatile compared to industry and market?
GLYC volatility
GLYC Average Weekly Movement15.9%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: GLYC is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: GLYC's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200352Harout Semerjianhttps://www.glycomimetics.com

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors.

GlycoMimetics, Inc. Fundamentals Summary

How do GlycoMimetics's earnings and revenue compare to its market cap?
GLYC fundamental statistics
Market CapUS$120.05m
Earnings (TTM)-US$53.87m
Revenue (TTM)US$92.63k

1,301x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GLYC income statement (TTM)
RevenueUS$92.63k
Cost of RevenueUS$0
Gross ProfitUS$92.63k
Other ExpensesUS$53.96m
Earnings-US$53.87m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.03
Gross Margin100.00%
Net Profit Margin-58,155.19%
Debt/Equity Ratio0%

How did GLYC perform over the long term?

See historical performance and comparison